The HealthCare segment at
) announced the commencement of the patient enrolment process for
a phase III study (COAST; n~75) on Stivarga.
ACTELION LTD (ALIOF): Get Free Report
ALEXION PHARMA (ALXN): Free Stock Analysis
AMGEN INC (AMGN): Free Stock Analysis Report
BAYER A G -ADR (BAYRY): Free Stock Analysis
To read this article on Zacks.com click here.
The study is evaluating Stivarga for the treatment of colorectal
cancer (CRC) subsequent to curative resection of liver metastases
and completion of all planned chemotherapy. Bayer will evaluate
whether treatment with Stivarga increases disease-free survival
(DFS) and overall survival (OS). The study will also assess the
safety and tolerability of the drug.
We note that the drug is co-promoted by Bayer and
) in the U.S. Amgen receives royalty payments from Bayer on all
global net sales of Stivarga as per the agreement. Stivarga is
already approved for the gastrointestinal stromal tumors (GlST)
and metastatic colorectal cancer (mCRC) indications in several
countries. The drug contributed €51 million to the HealthCare
segment's revenues in the third quarter of 2013.
We are encouraged by Bayer's progress with its newly launched
products. These products are expected to drive growth at the
HealthCare segment in the coming quarters. Bayer also had made
significant progress with its pipeline.
Earlier in the week, the HealthCare segment at Bayer announced
positive results from the PROTECT VIII (PROphylaxis in hemophilia
A patienTs via directly pEgylated long-aCTing rFVIII) study on
BAY94-9027. The study is evaluating the candidate for the
treatment of patients suffering from severe hemophilia A.
Bayer stated that the study met its primary endpoint of
protection from bleeds with fewer infusions. BAY94-9027 was also
successful in treating acute and breakthrough bleeds with 91%
cases resolved with one or two infusions. The candidate also
proved to be safe during the study.
Bayer currently carries a Zacks Rank #3 (Hold). Some
better-ranked stocks include
Alexion Pharmaceuticals, Inc.
). While Alexion holds a Zacks Rank #1 (Strong Buy),
Actelion carries a Zacks Rank #2 (Buy).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.